-
-
-
-
-
-
-
Leerink Partners on Rhythm Pharmaceuticals (RYTM): CHMP's positive opinion, language shows potential for broad EU labeling
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $130 at Needham
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Guggenheim
-
-
-
-
-
-
-
Rhythm Pharmaceuticals reports $57M Q4 revenue, 50% annual growth
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $150 at Morgan Stanley
-
-
-
-
-
-
-
Oppenheimer Downgrades Rhythm Pharmaceuticals (RYTM) to Perform
-
-
-
-
-
-
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
414,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

